Biora Historical Income Statement
| BIOR Stock | USD 1.93 0.14 7.82% |
Historical analysis of Biora Therapeutics income statement accounts such as Interest Income of 950.4 K, Depreciation And Amortization of 527.2 K or Interest Expense of 11.5 M can show how well Biora Therapeutics performed in making a profits. Evaluating Biora Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Biora Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Biora Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biora Therapeutics is a good buy for the upcoming year.
Biora |
About Biora Income Statement Analysis
Biora Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Biora Therapeutics shareholders. The income statement also shows Biora investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Biora Therapeutics Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Biora Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Biora Therapeutics. It is also known as Biora Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Biora Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Biora Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biora Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Biora Stock, please use our How to Invest in Biora Therapeutics guide.At this time, Biora Therapeutics' Tax Provision is relatively stable compared to the past year. As of 11/28/2024, Interest Expense is likely to grow to about 11.5 M, while Depreciation And Amortization is likely to drop slightly above 527.2 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 12.6M | 11.0M | 9.8M | 11.5M | Depreciation And Amortization | 1.4M | 907K | 555K | 527.3K |
Biora Therapeutics income statement Correlations
Click cells to compare fundamentals
Biora Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biora Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Tax Provision | (706K) | (37.5M) | (119K) | (420K) | 264K | 277.2K | |
| Net Interest Income | (8.6M) | (34.9M) | (12.6M) | (11.0M) | (10.7M) | (11.2M) | |
| Depreciation And Amortization | 6.9M | 5.1M | 1.4M | 907K | 555K | 527.3K | |
| Interest Expense | 9.2M | 34.9M | 12.6M | 11.0M | 9.8M | 11.5M | |
| Selling General Administrative | 61.3M | 75.4M | 68.5M | 38.0M | 38.1M | 44.4M | |
| Total Revenue | 144.0M | 74.3M | 1.2M | 305K | 4K | 3.8K | |
| Gross Profit | 43.5M | (19.1M) | (190K) | (602K) | 4K | 3.8K | |
| Other Operating Expenses | 284.1M | 269.5M | 119.1M | 62.1M | 67.1M | 63.8M | |
| Operating Income | (140.1M) | (195.2M) | (117.8M) | (61.8M) | (67.1M) | (70.5M) | |
| Net Income From Continuing Ops | (148.0M) | (192.5M) | (178.5M) | (48.8M) | (122.2M) | (128.3M) | |
| Ebit | (140.1M) | (195.2M) | (166.0M) | (38.3M) | (114.6M) | (120.3M) | |
| Research Development | 63.4M | 47.7M | 45.8M | 24.0M | 29.8M | 34.6M | |
| Ebitda | (133.2M) | (190.1M) | (164.6M) | (37.4M) | (114.1M) | (119.8M) | |
| Cost Of Revenue | 100.5M | 93.4M | 1.4M | 907K | 555K | 527.3K | |
| Total Operating Expenses | 183.6M | 176.1M | 119.1M | 62.1M | 67.1M | 101.1M | |
| Reconciled Depreciation | 6.3M | 5.1M | 1.4M | 907K | 596K | 566.2K | |
| Income Before Tax | (148.7M) | (230.1M) | (178.6M) | (49.3M) | (124.4M) | (130.6M) | |
| Total Other Income Expense Net | (8.6M) | (34.9M) | (60.8M) | 12.5M | (57.3M) | (54.4M) | |
| Net Income | (148.0M) | (192.5M) | (178.5M) | (48.8M) | (124.1M) | (130.3M) | |
| Income Tax Expense | (706K) | (37.5M) | (119K) | (420K) | (90K) | (94.5K) |
Pair Trading with Biora Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biora Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biora Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Biora Stock
| 0.81 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.87 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.95 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Biora Stock
| 0.91 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.81 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.62 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.6 | PHVS | Pharvaris BV | PairCorr |
| 0.4 | ESLAW | Estrella Immunopharma | PairCorr |
The ability to find closely correlated positions to Biora Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biora Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biora Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biora Therapeutics to buy it.
The correlation of Biora Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biora Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biora Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biora Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Biora Stock Analysis
When running Biora Therapeutics' price analysis, check to measure Biora Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biora Therapeutics is operating at the current time. Most of Biora Therapeutics' value examination focuses on studying past and present price action to predict the probability of Biora Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biora Therapeutics' price. Additionally, you may evaluate how the addition of Biora Therapeutics to your portfolios can decrease your overall portfolio volatility.